Medical oncology
1 – 50 of 550
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
(
- Contribution to journal › Letter
-
Mark
Towards improved cervical cancer screening in Ethiopia
2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial
(
- Contribution to journal › Article
-
Mark
Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours
2024) In BJU International(
- Contribution to journal › Article
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
(
- Contribution to journal › Article
-
Mark
Tattoos as a risk factor for malignant lymphoma: a population-based case–control study
(
- Contribution to journal › Article
-
Mark
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Article
-
Mark
Lars R Holsti (1926-2023), Big name in Finnish and Nordic oncology
(
- Contribution to journal › Letter
-
Mark
Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit
(
- Contribution to journal › Article
-
Mark
Optimal follow-up with somatostatin receptor PET/CT imaging in patients with small intestinal neuroendocrine tumours
2024) In Journal of Neuroendocrinology(
- Contribution to journal › Article
-
Mark
Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome (BIO-MUSE) : Protocol for a Translational Study
(
- Contribution to journal › Article
-
Mark
Progressive QTc prolongation and reduced heart rate variability in dementia with Lewy bodies compared to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50–70 year old AML patients
(
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
(
- Contribution to journal › Article
-
Mark
Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort : The Swedish Norwegian Testicular Cancer Group Experience
(
- Contribution to journal › Article
-
Mark
Retrospective evaluation of the predictive value of tumour burden at baseline [
68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT.
(
- Contribution to journal › Article
-
Mark
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
(
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
-
Mark
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
(
- Contribution to journal › Article
-
Mark
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE
(
- Contribution to journal › Article
-
Mark
The National Swedish Lymphoma Register – a systematic validation of data quality
(
- Contribution to journal › Article
- 2023
-
Mark
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors
(
- Contribution to journal › Article
-
Mark
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
(
- Contribution to journal › Article
-
Mark
Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: : a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
(
- Contribution to journal › Article
-
Mark
Increased incidence and improved survival in endometrial cancer in Sweden 1960-2014 : a population-based registry survey
(
- Contribution to journal › Article
-
Mark
Proteogenomics decodes the evolution of human ipsilateral breast cancer
(
- Contribution to journal › Article
-
Mark
Exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma– pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia
(
- Contribution to journal › Article
-
Mark
AI-based quantification of whole-body tumour burden on somatostatin receptor PET/CT
(
- Contribution to journal › Article
-
Mark
Exploring new prognostic biomarkers in Mantle Cell Lymphoma : a comparison of the circSCORE and the MCL35 score
(
- Contribution to journal › Article
-
Mark
HPV self-sampling versus healthcare provider collection on the effect of cervical cancer screening uptake and costs in LMIC : a systematic review and meta-analysis
(
- Contribution to journal › Article
-
Mark
Implementation of the measure of case discussion complexity to guide selection of prostate cancer patients for multidisciplinary team meetings
(
- Contribution to journal › Article
-
Mark
Averaging of absorbed doses : How matter matters
(
- Contribution to journal › Article
-
Mark
Validation of a prediction model for post-chemotherapy fibrosis in nonseminoma patients
(
- Contribution to journal › Article
-
Mark
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma : The Swedish MCL complete Project
(
- Contribution to journal › Article
-
Mark
Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms
(
- Contribution to journal › Scientific review
-
Mark
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer : data from the randomized SBII:2 trial
(
- Contribution to journal › Article
-
Mark
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
(
- Contribution to journal › Article
-
Mark
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
-
Mark
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma : results from a retrospective worldwide registry
(
- Contribution to journal › Article
-
Mark
Secondary malignancies among mantle cell lymphoma patients
(
- Contribution to journal › Article
-
Mark
Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer
(
- Contribution to journal › Article
-
Mark
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
(
- Contribution to journal › Article
-
Mark
Reply to V. Nardone et al
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
(
- Contribution to journal › Article
-
Mark
Evidence for distinct mechanisms of immune suppression in EBV-positive and EBV-negative Hodgkin lymphoma
(
- Contribution to journal › Article
- 2022
-
Mark
Advances in immune therapies in hematological malignancies
(
- Contribution to journal › Scientific review
-
Mark
The wait time to primary surgery in endometrial cancer–impact on survival and predictive factors : a population-based SweGCG study
(
- Contribution to journal › Article